VIVUS Announces Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting

VIVUS, Inc.

today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study, male diabetics receiving avanafil had significant improvement in erectile function. Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital, San Diego, CA, presented the results of the study during the poster session at the 47th European Association for the Study of Diabetes Annual Meeting in Lisbon, Portugal. Results of the study have been previously reported, but this was the first public European presentation of avanafil safety and efficacy data in diabetic patients. The study included 390 patients with type 1 and type 2 diabetes treated over 12 weeks with avanafil 100mg, 200mg, or placebo. Diabetics are disproportionately affected by erectile dysfunction, which can worsen with increased duration of disease, and these patients are often considered less responsive to therapy.